Evusheld: Preventing COVID-19 in High-Risk Patients

Learn about the practical role of this treatment option in preventing COVID-19 in high-risk patients. 




COVID-19 vaccines have been foundational in reducing the number of infections and severe outcomes associated with SARS-CoV2 infections. 

Unfortunately, a portion of individuals with immunocompromising conditions do not respond to these COVID-19 vaccines as well as healthy individuals. As public health measures (e.g., masking, physical distancing) are being removed across the country, patients with a lower immune response to vaccines are at elevated risk of infections and severe COVID-19 outcomes. 

Tixagevimab/Cilgavimab is a monoclonal antibody treatment that has been approved to be used to prevent COVID-19 infections in patients who are unable to mount an adequate immune response to COVID-19 vaccinations. 

This webinar recording reviews the practical role of this treatment option to prevent COVID-19 in high risk patients.

Learning objectives:

By the end of this course, you should be able to:  

  • Discuss the indications and recommendations for Tixagevimab/Cilgavimab in preventing COVID-19 in high-risk patients 
  • Identify potential candidates for Tixagevimab/Cilgavimab to prevent COVID-19 infections and severe outcomes 
  • Discuss the potential adverse effects and administration of Tixagevimab/Cilgavimab 
  • List potential roles for pharmacists in recommending Tixagevimab/Cilgavimab 

Course outline:

  • Webinar Recording (1 hour)
  • Program Evaluation


This course is brought to you by an educational grant from AstraZeneca.

Course at a glance:

  • 1 hour to complete
  • Course expiration date: October 1, 2023
  • Online
  • Completion requirement: Watch the webinar recording and complete the program evaluation

Who should take this course:

This learning activity may be of interest to both community & hospital pharmacists, those supporting heme-oncology, transplant, and immune-compromised patient groups.

Development Team:

  • Michael Boivin, BSc. Pharm
  • Jen Belcher, VP Strategic Initiatives and Membership, OPA

Cancelation Policy

Please refer to OPA’s Terms and Conditions of Purchase for cancellation policies.